Nirmatrelvir
Författaruppgift saknas
Tidskrift saknas · review PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för nirmatrelvir. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
28 träffarPreclinical evaluation of the SARS-CoV-2 M<sup>pro</sup> inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir.
Chen X, Huang X, Ma Q, Kuzmič P, Zhou B, Zhang S, Chen J, Xu J, Liu B, Jiang H, Zhang W, Yang C, Wu S, Huang J, Li H, Long C, Zhao X, Xu H, Sheng Y, Guo Y, Niu C, Xue L, Xu Y, Liu J, Zhang T, Spencer J, Zhu Z, Deng W, Chen X, Chen SH, Zhong N, Xiong X, Yang Z.
Nat Microbiol · research-article; journal article · DOI 10.1038/s41564-024-01618-9The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19.
Bege M, Borbás A.
Pharmaceutics · review-article; review; journal article · DOI 10.3390/pharmaceutics16020217Discovery and development of COVID-19 vaccines and therapeutics: nonclinical perspectives.
Khan N, Sathish J, Rohde CM.
J Toxicol Sci · journal article · DOI 10.2131/jts.49.79Structural Basis for the Inhibition of SARS-CoV-2 M<sup>pro</sup> D48N Mutant by Shikonin and PF-07321332.
Zhao Z, Zhu Q, Zhou X, Li W, Yin X, Li J.
Viruses · research-article; journal article · DOI 10.3390/v16010065Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach.
Havranek B, Demissie R, Lee H, Lan S, Zhang H, Sarafianos S, Ayitou AJ, Islam SM.
J Chem Inf Model · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jcim.3c01269Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.
Bakos É, Temesszentandrási-Ambrus C, Özvegy-Laczka C, Gáborik Z, Sarkadi B, Telbisz Á.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms241411237In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
Kiso M, Furusawa Y, Uraki R, Imai M, Yamayoshi S, Kawaoka Y.
Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-023-39704-xBinding kinetics study of SARS-CoV-2 main protease and potential inhibitors <i>via</i> molecular dynamics simulations.
Li X, Fang Z, Li D, Li Z.
Phys Chem Chem Phys · journal article · DOI 10.1039/d2cp05911hStructural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332.
Zhou Y, Wang W, Zeng P, Feng J, Li D, Jing Y, Zhang J, Yin X, Li J, Ye H, Wang Q.
Biochem Biophys Res Commun · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2023.03.043Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.
Rosenke K, Lewis MC, Feldmann F, Bohrnsen E, Schwarz B, Okumura A, Bohler WF, Callison J, Shaia C, Bosio CM, Lovaglio J, Saturday G, Jarvis MA, Feldmann H.
JCI Insight · research support, n.i.h., intramural; research-article; journal article · DOI 10.1172/jci.insight.166485Total synthesis of antiviral drug, nirmatrelvir (PF-07321332).
Shekhar C, Nasam R, Paipuri SR, Kumar P, Nayani K, Pabbaraja S, Mainkar PS, Chandrasekhar S.
Tetrahedron Chem · brief-report; journal article · DOI 10.1016/j.tchem.2022.100033Paxlovid: Mechanism of Action, Synthesis, and <i>In Silico</i> Study.
Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E.
Biomed Res Int · review-article; review; journal article · DOI 10.1155/2022/7341493Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development.
Singh RSP, Walker GS, Kadar EP, Cox LM, Eng H, Sharma R, Bergman AJ, Van Eyck L, Hackman F, Toussi SS, Kalgutkar AS, Obach RS.
Clin Pharmacol Ther · research support, non-u.s. gov't; journal article · DOI 10.1002/cpt.2683The Remarkable Selectivity of Nirmatrelvir.
Duveau DY, Thomas CJ.
ACS Pharmacol Transl Sci · article-commentary; journal article · DOI 10.1021/acsptsci.2c00065PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
Hau RK, Wright SH, Cherrington NJ.
Clin Transl Sci · brief-report; journal article; research support, n.i.h., extramural · DOI 10.1111/cts.13292Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT.
Alvarado YJ, Olivarez Y, Lossada C, Vera-Villalobos J, Paz JL, Vera E, Loroño M, Vivas A, Torres FJ, Jeffreys LN, Hurtado-León ML, González-Paz L.
Comput Biol Chem · research-article; journal article · DOI 10.1016/j.compbiolchem.2022.107692Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
Kneller DW, Li H, Phillips G, Weiss KL, Zhang Q, Arnould MA, Jonsson CB, Surendranathan S, Parvathareddy J, Blakeley MP, Coates L, Louis JM, Bonnesen PV, Kovalevsky A.
Nat Commun · research support, n.i.h., intramural; research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1038/s41467-022-29915-zStructural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
Greasley SE, Noell S, Plotnikova O, Ferre R, Liu W, Bolanos B, Fennell K, Nicki J, Craig T, Zhu Y, Stewart AE, Steppan CM.
J Biol Chem · research-article; journal article · DOI 10.1016/j.jbc.2022.101972Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
Li J, Lin C, Zhou X, Zhong F, Zeng P, Yang Y, Zhang Y, Yu B, Fan X, McCormick PJ, Fu R, Fu Y, Jiang H, Zhang J.
J Virol · research-article; journal article · DOI 10.1128/jvi.02013-21Nirmatrelvir Plus Ritonavir: First Approval.
Lamb YN.
Drugs · review-article; review; journal article · DOI 10.1007/s40265-022-01692-5Computational Screening of Phenylamino-Phenoxy-Quinoline Derivatives against the Main Protease of SARS-CoV-2 Using Molecular Docking and the ONIOM Method.
Patnin S, Makarasen A, Vijitphan P, Baicharoen A, Chaivisuthangkura A, Kuno M, Techasakul S.
Molecules · research-article; journal article · DOI 10.3390/molecules27061793[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
Reina J, Iglesias C.
Rev Esp Quimioter · research-article; review; journal article · DOI 10.37201/req/002.2022Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
Ullrich S, Ekanayake KB, Otting G, Nitsche C.
Bioorg Med Chem Lett · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2022.128629Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Eng H, Dantonio AL, Kadar EP, Obach RS, Di L, Lin J, Patel NC, Boras B, Walker GS, Novak JJ, Kimoto E, Singh RSP, Kalgutkar AS.
Drug Metab Dispos · journal article · DOI 10.1124/dmd.121.000801Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Hung YP, Lee JC, Chiu CW, Lee CC, Tsai PJ, Hsu IL, Ko WC.
Antibiotics (Basel) · other; journal article · DOI 10.3390/antibiotics11020220Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M<sup>pro</sup>.
Ngo ST, Nguyen TH, Tung NT, Mai BK.
RSC Adv · research-article; journal article · DOI 10.1039/d1ra08752eCrystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.
Zhao Y, Fang C, Zhang Q, Zhang R, Zhao X, Duan Y, Wang H, Zhu Y, Feng L, Zhao J, Shao M, Yang X, Zhang L, Peng C, Yang K, Ma D, Rao Z, Yang H.
Protein Cell · letter; research support, non-u.s. gov't · DOI 10.1007/s13238-021-00883-2